Unearthing new genomic markers of drug response by improved measurement of discriminative power

BACKGROUND: Oncology drugs are only effective in a small proportion of cancer patients. Our current ability to identify these responsive patients before treatment is still poor in most cases. Thus, there is a pressing need to discover response markers for marketed and research oncology drugs. Screen...

Descripción completa

Detalles Bibliográficos
Autores principales: Dang, Cuong C., Peón, Antonio, Ballester, Pedro J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801688/
https://www.ncbi.nlm.nih.gov/pubmed/29409485
http://dx.doi.org/10.1186/s12920-018-0336-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801688/
https://www.ncbi.nlm.nih.gov/pubmed/29409485
http://dx.doi.org/10.1186/s12920-018-0336-z

Ejemplares similares